Ex vivo enrichment of malignant carcinoma cells in primary culture

Pathology

Volumn 39, Issue 5, 2007, Pages 491-494

  Heinzman, Jamie M ^a   Brower, Stacey L ^a,c   Bush, Jason E ^a   Silverman, Jan F ^b  

^a Precision Therapeutics Inc   (United States)

^b ALLEGHENY GENERAL HOSPITAL   (United States)

^c NONE   (United States)

Author keywords

Cancer; Chemoresponse; Cytopathology; Malignant cells; Primary culture

Indexed keywords

ARTICLE; BREAST; BREAST CANCER; CANCER DIAGNOSIS; CELL CULTURE; COLON; COLON CANCER; CONTROLLED STUDY; CYTOPATHOLOGY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG; LUNG CANCER; OVARY; OVARY CANCER; PAPANICOLAOU TEST;

CARCINOMA; CELL CULTURE TECHNIQUES; DRUG SCREENING ASSAYS, ANTITUMOR; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; TUMOR CELLS, CULTURED;

EID: 34548835810     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020701569949     Document Type: Article

References (9)

1. Koechli O, Sevin B, Perras J, et al. Growth characteristics of nonmalignant cells in the ATP cell viability assay. Oncology 1994; 51: 35-41.
2. Krasna L, Dudorkinova D, Vedralova J, et al. Large expansion of morphologically teterogenous mammary epithelial cells, including the luminal phenotype, from human breast tumours. Breast Cancer Res Treat 2002; 71: 219-35.
3. Walter-Yohrling J, Cao X, Callahan M, et al. Identification of genes expressed in malignant cells that promote invasion. Cancer Res 2003; 63: 8939-47.
4. Ochs RL, Fensterer J, Ohori NP, et al. Evidence for the isolation, growth, and characterization of malignant cells in primary cultures of human tumors. In Vitro Cell Dev Biol Anim 2003; 39: 63-70.
5. Kothari M, Ali S, Buluwela L, et al. Purified malignant mammary epithelial cells maintain hormone responsiveness in culture. Br J Cancer 2003; 88: 1071-6.
6. Ochs RL, Burholt D, Kornblith P. The ChemoFx assay: an ex vivo cell culture assay for predicting anticancer drug responses. Methods Mol Med 2005; 110: 155-72.
7. Gallion H, Christopherson WA, Coleman RL, et al. Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay. Int J Gynecol Cancer 2006; 16: 194-201.
8. Samson DJ, Seidenfeld J, Ziegler K, Aronson N. Chemotherapy sensitivity and resistance assays: a systematic review. J Clin Oncol 2004; 22: 3618-30.
9. Ness RB, Wisniewski SR, Eng H, Christopherson W. Cell viability assay for drug testing in ovarian cancer: in vitro cell kill versus clinical response. Anticancer Res 2002; 22: 1145-9.